Open-label trial of atomoxetine hydrochloride in adults with ADHD.

• Background: While atomoxetine is an established treatment for attention-deficit/hyperactivity disorder in children, few studies have examined its efficacy for adults. Methods: Open-label trial of atomoxetine in 20 individuals with ADHD, aged 19-47 years, for 10 weeks, and a total of one year for responders. Results: Ten patients met primary efficacy criteria at 10 weeks. Only one patient completed the whole study. Six patients discontinued before 10 weeks and thirteen at 10 weeks or later, mainly because of side-effects (aggression, depressed mood, raised liver enzymes, thyroid hormones, diastolic blood pressure), decreasing efficacy or non-compliance. Conclusion: Fifty percent responded to treatment, but only one patient (5%) felt sufficient improvement to continue for one year. Dosage may have been too low, and baseline impairment too high, for atomoxetine to have sufficient effect on ADHD symptoms in our group of adults. The majority had few side-effects, but several terminated treatment because of adverse effects.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Psykiatri (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Psychiatry (hsv//eng)

Nyckelord

Adrenergic Uptake Inhibitors

Administration & dosage

Adverse effects

Adult

Attention Deficit Disorder with Hyperactivity

Drug therapy

Drug Administration Schedule

Female

Humans

Intention to Treat Analysis

Longitudinal Studies

Male

Middle Aged

Patient Selection

Propylamines

Administration & dosage

Adverse effects

Time

Treatment Outcome

Adult

long-term trial

adults

atomoxetine

ADHD

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)